Your browser doesn't support javascript.
loading
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri, Sumita; Moore, Wendy; Gibson, Peter G; Leigh, Richard; Bourdin, Arnaud; Maspero, Jorge; Barros, Manuel; Buhl, Roland; Howarth, Peter; Albers, Frank C; Bradford, Eric S; Gilson, Martyn; Price, Robert G; Yancey, Steven W; Ortega, Hector.
Afiliação
  • Khatri S; Respiratory Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Moore W; Section of Pulmonary, Critical Care, Allergy and Immunologic Disease, Wake Forest School of Medicine, Winston-Salem, NC.
  • Gibson PG; Priority Research Center for Healthy Lungs and Center of Excellence in Severe Asthma, University of Newcastle, Newcastle, Australia.
  • Leigh R; Department of Medicine and Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Bourdin A; Department of Respiratory Diseases PhyMedExp, University of Montpellier, Montpellier, France; Hôpital Arnaud de Villeneuve, CHU Montpellier, Montpellier, France.
  • Maspero J; Fundación Cidea Allergy and Respiratory Research Unit, Buenos Aires, Argentina.
  • Barros M; School of Medicine, Universidad de Valparaiso, Valparaiso, Chile; Hospital Carlos van Buren, Valparaiso, Chile.
  • Buhl R; Pulmonary Department, Mainz University Hospital, Mainz, Germany.
  • Howarth P; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton and NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, United Kingdom; Global Respiratory Franchise, GSK House, Brentford, Middlesex, United Kingdom.
  • Albers FC; Respiratory Medical Franchise, GSK, Research Triangle Park, NC.
  • Bradford ES; Respiratory Therapeutic Area, GSK, Research Triangle Park, NC.
  • Gilson M; Respiratory Research and Development, GSK, Uxbridge, Middlesex, United Kingdom.
  • Price RG; Clinical Statistics, GSK, Stevenage, Hertfordshire, United Kingdom.
  • Yancey SW; Respiratory Therapeutic Area, GSK, Research Triangle Park, NC.
  • Ortega H; Respiratory, Medical Affairs, GSK, La Jolla, Calif. Electronic address: hortega@gossamerbio.com.
J Allergy Clin Immunol ; 143(5): 1742-1751.e7, 2019 05.
Article em En | MEDLINE | ID: mdl-30359681
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Eosinofilia / Eosinófilos / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Eosinofilia / Eosinófilos / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2019 Tipo de documento: Article